| 周 静,彭春雷,范震宇,倪 华,范裕兵.参附注射液联合奥西替尼治疗晚期EGFR阳性非小细胞肺癌患者疗效及对患者免疫功能的影响[J].,2022,(10):1919-1922 |
| 参附注射液联合奥西替尼治疗晚期EGFR阳性非小细胞肺癌患者疗效及对患者免疫功能的影响 |
| Efficacy of Shenfu Injection Combined with Osimertinib in the Treatment of Patients with Advanced EGFR-positive NSCLC and Its Effect on the Immune Function of Patients |
| 投稿时间：2021-10-09 修订日期：2021-10-31 |
| DOI：10.13241/j.cnki.pmb.2022.10.025 |
| 中文关键词: 参附注射液 奥西替尼 晚期肺癌 EGFR阳性 非小细胞肺癌 疗效 免疫功能 |
| 英文关键词: Shenfu injection Osimertinib Advanced lung cancer EGFR positive Non-small cell lung cancer Curative effect Immune function |
| 基金项目:江苏省卫计委预防医学科研项目（Y2018038） |
|
| 摘要点击次数: 505 |
| 全文下载次数: 229 |
| 中文摘要: |
| 摘要 目的：探讨分析参附注射液联合奥西替尼治疗晚期EGFR阳性非小细胞肺癌（Non-small cell lung cancer，NSCLC）患者疗效及对患者免疫功能的影响。方法：选择2018年6月~2020年12月我院收治的EGFR突变阳性晚期NSCLC患者96例，随机分为观察组50例、对照组46例，对照组给予奥西替尼口服治疗，观察组在对照组基础上给予参附注射液，两组均治疗16周。比较两组治疗临床疗效、免疫功能指标及患者生活质量评分结果。结果：治疗前，两组T淋巴细胞亚群水平和EORCT-QLQ-C30评分差异均无统计学意义（P>0.05）；治疗后，与对照组相比，观察组患者治疗有效率、CD4+/CD8+比值、功能领域及总体健康状况评分均显著增加，而外周血CD8+水平、症状领域评分均显著降低（P<0.05）。结论：参附注射液联合奥西替尼治疗晚期EGFR阳性NSCLC患者可有效提高临床治疗效果，改善患者机体免疫功能并提高患者生活质量，值得临床推广。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate and analyze the therapeutic effect of Shenfu injection combined with osimertinib in the treatment of patients with advanced EGFR-positive non-small cell lung cancer and its effect on the immune function of patients. Methods: A total of 96 EGFR mutation-positive advanced NSCLC patients admitted to our hospital from June 2018 to December 2020 were randomly divided into observation group of 50 cases and control group of 46 cases. The control group was given oral treatment with osimertinib, and the observation group Shenfu injection was given on the basis of the control group, and both groups were treated for 16 weeks. The clinical efficacy, immune function indicators and patient quality of life scores were compared between the two groups. Results: Before treatment, there was no significant difference in the levels of T lymphocyte subsets and EORCT-QLQ-C30 scores between the two groups (P>0.05); After treatment, compared with the control group, the observation group patients' treatment effectiveness, CD4+/CD8+ ratio, functional areas and overall health status scores were significantly increased, while the peripheral blood CD8+ level and symptom area scores were significantly reduced (P<0.05). Conclusion: Shenfu injection combined with Ositinib in the treatment of patients with advanced EGFR-positive NSCLC can effectively improve the clinical treatment effect, improve the immune function of the patient and improve the quality of life of the patient, and it is worthy of clinical promotion. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
